Pharma stock jumps 3% after acquiring 100% stake in Apnar Pharma for ₹91 Cr

Synopsis: This small-cap pharma company was in the news following the acquisition of the 100% stake it made in Apnar Pharma. The acquisition is valued at around Rs 91 crore on an enterprise value basis and strengthens its presence in the regulated market, as Apnar has manufacturing facilities that are US FDA, UK MHRA, and Health Canada approved. 

This company, which manufactures and develops affordable and high-quality complex generics certified by global food and drug authorities, had its shares in the news when following the announcement of a 100% stake acquisition in Apnar Pharma, which specialises in the licensing, development, and manufacturing of generic formulations for regulated markets like the US, UK & Canada.

With a market cap of Rs 3,762 crore, the shares of Senores Pharmaceuticals Ltd gained about 3.5% and reached their high at Rs 844 compared to their previous day’s closing price at Rs 815.55 and are trading at a PE of 43.2, whereas their industry PE is 30.6. The shares have given a return of 47% since their listing in December last year. 

About the Acquisition

Senores Pharmaceuticals has announced the acquisition of a 100% stake in Apnar Pharma Private Limited, a move that fits naturally into its long-term growth strategy. The deal will be completed in two phases, after which Apnar Pharma will operate as a wholly owned subsidiary. Rather than building capacity from scratch, Senores is choosing to strengthen its business by bringing an existing, well-established manufacturing setup into the group.

What makes Apnar Pharma an attractive acquisition is its regulatory-approved manufacturing facility near Vadodara, which holds approvals from the US FDA, UK MHRA, and Health Canada. These approvals are difficult and time-consuming to obtain, and they give senores immediate access to regulated global markets. Along with this, Apnar Pharma’s focus on generic pharmaceutical formulations complements Senores’ existing product and market strategy.

The acquisition is valued at around Rs 91 crore on an enterprise value basis, structured through a mix of debt assumption and cash payment. Senores will take over roughly Rs 76 crore of existing debt and liabilities while paying about Rs 15 crore in cash. The staggered structure will reach 75% completion by March 2026 and the remaining 25% by Q2 FY27, allowing the company to manage integration and cash flows in a measured manner.

Beyond regulatory benefits, the acquisition of Apnar Pharma adds meaningful business strength to Senores Pharmaceuticals. The deal brings with it 5 approved ANDAs across 15 strengths, including 3 products that are already validated and ready for immediate commercialisation, giving Senores a quicker path to revenue. These products together address a large market opportunity of around US$722 million, significantly widening the company’s growth runway.

At the operational level, the acquisition improves backward integration by adding in-house manufacturing, reducing dependence on external partners, and improving cost control, margins, and supply reliability. The facility also offers scalable capacity across tablets, capsules, and bottles, allowing Senores to shift select US manufacturing to India and improve operating leverage. Overall, the deal strengthens Senores’ product pipeline, manufacturing economics, and CDMO/CMO opportunities, supporting sustainable long-term growth.

Overall, this acquisition strengthens Senores’ manufacturing backbone and enhances its ability to scale operations in regulated markets. By integrating Apnar Pharma’s facilities and expertise, Senores is positioning itself for more stable and sustainable growth while improving control over production and expanding its global reach without taking on excessive execution risk.

Financials and more

The revenue from operations is at Rs 162 crore in Q2 FY26 versus Rs 101 crore in Q2 FY25, which is a growth of about 60 per cent. Similarly, the net profit has also increased from Rs 13 crore in Q2 FY25 to Rs 30 crore in Q2 FY26, which is a growth of about 130 per cent.

Apnar Pharma, incorporated on 12 December 2014, is a privately held pharmaceutical company focused on the development and manufacturing of generic formulations for regulated markets such as the US, UK, and Canada. The company operates a dedicated manufacturing facility in Jambusar, Gujarat, underscoring its commitment to quality-led production. With approvals from the USFDA, MHRA, and Health Canada, Apnar Pharma has established itself as a trusted manufacturer capable of meeting stringent international regulatory standards.

Senores Pharmaceuticals is a forward-looking pharmaceutical company focused on building a meaningful presence in global markets by combining innovation with high-quality manufacturing. Guided by experienced industry veterans, the company is steadily growing with a clear emphasis on developing niche, complex, and speciality pharmaceutical products that meet international quality standards. 

With a team driven by the goal of making healthcare more affordable and accessible worldwide, Senores continues to expand its capabilities to address the evolving needs of the global healthcare industry while creating sustainable long-term value. 

Written by Leon Mendonca. 

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma stock jumps 3% after acquiring 100% stake in Apnar Pharma for ₹91 Cr appeared first on Trade Brains.